Some people infected with HIV are teeming with virus, but don’t get sick. Their resistive powers probably come from a mix of ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

A new study published in the Journal of Clinical Tuberculosis and Other Mycobacterial Diseases showed that two ...

From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

Gilead and Merck said their once-weekly pill to treat HIV resulted in a comparable level of viral suppression compared to a ...

GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Clarence Peeples is part of a small club in the HIV community. He is using his experiences to help fight the virus among ...

Improving HIV Treatment in Children and Adolescents -- The Right Way July 18, 2024 — Globally, around 2.6 million children and adolescents are currently living with HIV, the majority of them in ...

Indigenous communities in Latin America say they are being excluded from the global HIV/AIDS response, leaving them without ...